Drug Profile
Research programme: Alzheimer's disease therapeutics - ReNetX Bio/AstraZeneca
Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Yale University
- Developer AstraZeneca; ReNetX Bio
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 01 May 2012 Early research in Alzheimer's disease in USA (unspecified route)